Shanghai RAAS: Controlling shareholder increases stake, triggering 1% threshold

Shanghai RAAS Blood Products (SZSE:002252) announced that its controlling shareholder, Haiyingkang (Qingdao) Medical Technology, has increased its holdings in the company. Between May 22, 2025, and June 19, 2025, Haiyingkang acquired 14,027,600 shares through the Shenzhen Stock Exchange's trading system, representing 0.21% of Shanghai RAAS's total share capital. This purchase increased Haiyingkang's voting rights from 28.80% to 29.01%, triggering the disclosure requirement as it surpassed the 1% threshold. Haiyingkang's initial plan, announced on May 22, 2025, involves increasing its stake by between CNY 250 million and CNY 500 million. As of June 19, 2025, Haiyingkang directly holds 1,488,605,652 shares, or 22.43% of the company, and controls voting rights for an additional 437,069,656 shares (6.58%) through a voting proxy from Grifols, S.A., bringing its total control to 29.01%. The company states the increase reflects confidence in Shanghai RAAS's future prospects and long-term investment value. The company noted that there are no laws and regulations restricting the shareholder from increasing their holdings and that the plan remains ongoing.